All In Biotech

Drug Trial Radar · NCT04544774

The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy

The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy: An Academic Multicentre Clinical Study

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jul 16, 2020

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AZ Sint-Jan AV
First posted
Sep 10, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years

Summary

As written by the sponsor on the registry.

This prospective multicentric academic NAPT study aims to compile a database of all patients who initiate immunotherapy. The NAPT will take place before, during and after AIT to evaluate the cost and effectiveness of the treatment. The study consists of 4 visits and 2 telephone contacts that are repeated annually for 3 years. This study will be conducted in 2 hospitals: UZ Leuven and AZ ST. Jan Brugge on the consultation Ear, Nose and Throat Diseases (ENT) and the department of Internal Medicine / Allergology

Conditions

  • Perennial Allergic Rhinitis
  • Seasonal Allergic Rhinitis
  • Local Allergic Rhinitis

Interventions

  • AITDrug

    AIT for airborn allergens (SCIT/SLIT)

  • NAPTDiagnostic test

    NAPT test with airborn allergens ( HDM, Threes, Grasses)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The effectiveness of AIT treatment assessed by the change in the blood concentration in total en specific IgE .Time frame: before start AIT, every 6 months en after 3 years
  2. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the Lebelscore.Time frame: Before start AIT, every 6 months en after 3 years
  3. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the SNOT-22.Time frame: Before start AIT, every 6 months en after 3 years
  4. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the VAS.Time frame: Before start AIT, every 6 months en after 3 years
  5. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the TNSS.Time frame: Before start AIT, every 6 months en after 3 years
  6. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the ACT.Time frame: Before start AIT, every 6 months en after 3 years
  7. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the RQLQ.Time frame: Before start AIT, every 6 months en after 3 years
  8. The effectiveness of AIT treatment assessed by the change in quality of life meassured by the TRE.Time frame: Before start AIT, every 6 months en after 3 years
  9. The effectiveness of AIT treatment assessed by the change in the PNIF value.Time frame: Before start AIT, every 6 months en after 3 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • AZ Sint-Jan

    Bruges, Belgium · Not yet recruiting

  • UZ Leuven

    Leuven, Vlaam Brabant, Belgium · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.